Sara Bonstein Sells 58,400 Shares of Insmed, Inc. (NASDAQ:INSM) Stock

Insmed, Inc. (NASDAQ:INSM - Get Free Report) CFO Sara Bonstein sold 58,400 shares of the firm's stock in a transaction dated Monday, July 21st. The shares were sold at an average price of $102.67, for a total value of $5,995,928.00. Following the completion of the sale, the chief financial officer directly owned 73,505 shares in the company, valued at approximately $7,546,758.35. This represents a 44.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Sara Bonstein also recently made the following trade(s):

• On Monday, July 7th, Sara Bonstein sold 57,764 shares of Insmed stock. The stock was sold at an average price of $95.86, for a total value of $5,537,257.04.
• On Monday, June 23rd, Sara Bonstein sold 57,765 shares of Insmed stock. The stock was sold at an average price of $101.78, for a total value of $5,879,321.70.
• On Tuesday, June 10th, Sara Bonstein sold 57,766 shares of Insmed stock. The shares were sold at an average price of $89.12, for a total transaction of $5,148,105.92.
• On Tuesday, June 3rd, Sara Bonstein sold 1,579 shares of Insmed stock. The stock was sold at an average price of $71.50, for a total transaction of $112,898.50.
• On Wednesday, May 14th, Sara Bonstein sold 1,634 shares of Insmed stock. The shares were sold at an average price of $65.61, for a total value of $107,206.74.
• On Tuesday, May 13th, Sara Bonstein sold 8,870 shares of Insmed stock. The stock was sold at an average price of $67.81, for a total transaction of $601,474.70.

Insmed Stock Performance

Shares of NASDAQ INSM traded up $0.47 during trading hours on Friday, reaching $103.99. 889,696 shares of the stock were exchanged, compared to its average volume of 2,757,383. The firm has a market capitalization of $19.73 billion, a price-to-earnings ratio of -17.49 and a beta of 0.90. The company has a debt-to-equity ratio of 11.38, a quick ratio of 5.44 and a current ratio of 5.86. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $106.83. The stock's fifty day simple moving average is $89.86 and its 200 day simple moving average is $79.45.

Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). The firm had revenue of $92.82 million for the quarter, compared to the consensus estimate of $91.63 million. Insmed had a negative return on equity of 446.98% and a negative net margin of 265.93%. Insmed's revenue for the quarter was up 22.9% on a year-over-year basis. During the same quarter last year, the business posted ($1.06) EPS. Sell-side analysts predict that Insmed, Inc. will post -4.56 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Royal Bank Of Canada boosted their target price on Insmed from $99.00 to $106.00 and gave the stock an "outperform" rating in a research report on Wednesday, June 11th. Bank of America upped their price objective on Insmed from $94.00 to $109.00 and gave the company a "buy" rating in a report on Wednesday, June 11th. The Goldman Sachs Group boosted their target price on Insmed from $100.00 to $112.00 and gave the company a "buy" rating in a research note on Wednesday, June 11th. Wells Fargo & Company upped their price objective on Insmed from $119.00 to $130.00 and gave the stock an "overweight" rating in a research report on Tuesday. Finally, Mizuho upped their price objective on Insmed from $96.00 to $110.00 and gave the stock an "outperform" rating in a research report on Wednesday, June 11th. One analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $109.20.

Institutional Investors Weigh In On Insmed

Large investors have recently modified their holdings of the business. LRI Investments LLC acquired a new stake in shares of Insmed during the 2nd quarter valued at $59,000. IFP Advisors Inc boosted its holdings in shares of Insmed by 29.5% during the 2nd quarter. IFP Advisors Inc now owns 2,423 shares of the biopharmaceutical company's stock valued at $244,000 after acquiring an additional 552 shares in the last quarter. Maryland State Retirement & Pension System acquired a new stake in shares of Insmed during the 2nd quarter valued at $873,000. KLP Kapitalforvaltning AS boosted its holdings in shares of Insmed by 10.5% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 37,800 shares of the biopharmaceutical company's stock valued at $3,804,000 after acquiring an additional 3,600 shares in the last quarter. Finally, Chung Wu Investment Group LLC bought a new position in Insmed during the 2nd quarter worth $173,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.